Merck & Co., Inc. (0QAH.IL)
IOB - IOB Delayed price. Currency in USD
Add to watchlist
At close: 07:14PM BST
| Previous close | 130.80 |
| Open | 131.02 |
| Bid | 0.00 x N/A |
| Ask | 136.00 x N/A |
| Day's range | 129.82 - 152.05 |
| 52-week range | 99.15 - 152.05 |
| Volume | |
| Avg. volume | 164,839 |
| Market cap | 331.654B |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | 107.13 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.92 (2.83%) |
| Ex-dividend date | 14 Sept 2023 |
| 1y target est | N/A |
- Business Wire
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
RAHWAY, N.J., May 15, 2024--Merck to Present New Data at 2024 ASCO Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
- Business Wire
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
RAHWAY, N.J., May 13, 2024--Merck Update on KeyVibe-010 Evaluating Coform of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients W/ Resected High-Risk Melanoma
- Business Wire
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
RAHWAY, N.J., May 09, 2024--Merck Provides Update on Phase 3 KEYNOTE-B21 Trial
© 2024 Yahoo. All rights reserved.